Technologies

Unmet Need
Prostate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy. Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy. However existing anti-PSMA antibodies have several drawbacks, including limited commercial availability, poorly defined epitopes, and lack of data on cross-reactivity towards GCPII paralogs and orthologs.

Technology Overview
The technology includes four novel murine monoclonal antibodies (mAbs) that recognize human PSMA. One of these novel mAbs, 5D3, has approximately 10-fold higher affinity for PSMA than the clinically validated mAb J591 and therefore is a prime candidate for the development of next-generation theranostic agents targeting PSMA.